Fornaro M, Stubbs B, De Berardis D, Iasevoli F, Solmi M, Veronese N, Carano A, Perna G, De Bartolomeis A
New York State Psychiatric Institute (NYPSI); Columbia University, NYC, NY, USA.
Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK; Health Service and Population Research Department, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK.
Clin Pract Epidemiol Ment Health. 2016 Dec 23;12:142-157. doi: 10.2174/1745017901612010142. eCollection 2016.
Though often perceived as a "silver bullet" treatment for bipolar disorder (BD), lithium has seldom reported to lose its efficacy over the time.
The aim of the present study was to assess cases of refractoriness toward restarted lithium in BD patients who failed to preserve maintenance.
Treatment trajectories associated with re-instituted lithium following loss of achieved lithium-based maintenance in BD were retrospectively reviewed for 37 BD-I patients (median age 52 years; F:M=17:20 or 46% of the total) over an 8.1-month period on average.
In our sample only 4 cases (roughly 11% of the total, of whom F:M=2:2) developed refractoriness towards lithium after its discontinuation. Thirty-three controls (F:M=15:18) maintained lithium response at the time of re-institution. No statistically significant difference between cases and controls was observed with respect to a number of demographic and clinical features but for time spent before first trial ever with lithium in life (8.5 3 years; U=24.5, Z=-2.048, p=.041) and length of lithium discontinuation until new therapeutic attempt (5.5 2 years; U=8, Z=-2.927, p=.003) between cases controls respectively. Tapering off of lithium was significantly faster among cases controls (1 7 days; U=22, Z=-2.187), though both subgroups had worrisome high rates of poor adherence overall.
Although intrinsic limitations of the present preliminary assessment hamper the validity and generalizability of overall results, stating the clinical relevance of the topic further prospective research is warranted. The eventual occurrence of lithium refractoriness may indeed be associated with peculiar course trajectories and therapeutic outcomes ultimately urging the prescribing clinicians to put efforts in preserving maintenance of BD in the absence of any conclusive research insight on the matter.
尽管锂盐常被视为治疗双相情感障碍(BD)的“万灵药”,但很少有报告称其疗效会随时间丧失。
本研究旨在评估双相情感障碍患者在维持治疗失败后重新启用锂盐时出现难治性的病例。
回顾性分析了37例双相I型障碍患者(中位年龄52岁;女性:男性=17:20,占总数的46%)在平均8.1个月的时间里,在基于锂盐的维持治疗失败后重新启用锂盐的治疗轨迹。
在我们的样本中,只有4例(约占总数的11%,其中女性:男性=2:2)在停用锂盐后出现了对锂盐的难治性。33例对照者(女性:男性=15:18)在重新启用时维持了锂盐反应。病例组和对照组在一些人口统计学和临床特征方面未观察到统计学上的显著差异,但病例组和对照组在首次使用锂盐之前的时间(8.5±3年;U=24.5,Z=-2.048,p=0.041)以及停用锂盐至新的治疗尝试的时间(5.5±2年;U=8,Z=-